- Opinion: STAT+: I’m a cardiologist. I’m not sure the new cholesterol drug enlicitide is a game-changer“In truth, I don’t anticipate prescribing patterns changing immediately,” cardiologist Vishal Khetpal writes of the new cholesterol drug Lipfendra.STAT · 3d ago↗ source
- STAT+: Federal health quality research grants worth $109 million ended earlyAt least 78 AHRQ grants worth $200 million have been affected by "non-award" notices; it's estimated those grants had $109.2 million in funding remaining.STAT · 3d ago↗ source
- Celldex ends skin disease program after failing phase 2 testA phase 2 study of Celldex’s barzolvolimab in a chronic skin disease has missed its primary endpoint, driving the biotech to end development in the indication and raising doubts about an upcoming e…